A5068462965- Colorectal Cancer Screening and Detection
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Colorectal and Anal Carcinomas
- Digestive system and related health
Exact Sciences (United States)
2015-2023
Abstract High-specificity colorectal cancer screening is desirable to triage patients <50 years for colonoscopy; however, most endorsed tests have not been rigorously evaluated in younger populations. This prospective cross-sectional study determined the specificity of multitarget stool DNA (mt-sDNA) test an average-risk population 45 49 year-olds. Specificity was primary outcome and measured participants without or advanced precancerous lesions [APL– adenomas (AA), sessile serrated...
Emerging colorectal cancer trends demonstrate increased incidence and mortality in younger populations, prompting consideration of average-risk screening initiation at age 45 versus 50 years. However, test performance characteristics adults 45-49 years have been minimally described. To inform the biologic rationale for multi-target stool DNA (mt-sDNA) patients, we analyzed compared tissue levels methylation (
INTRODUCTION: Colorectal cancer (CRC) screening is broadly endorsed for individuals 50–75 years of age. Given recent increases in CRC incidence and mortality patients <50 old, the American Cancer Society now recommends initiation average-risk at age 45 (Wolf AMD CA J Clin 2018). The performance recommended tests, including multi-target stool DNA (mt-sDNA; marketed as Cologuard™) test, has been minimally described populations under 50 old. To address this knowledge gap, we conducted a...
<div>Abstract<p>High-specificity colorectal cancer screening is desirable to triage patients <50 years for colonoscopy; however, most endorsed tests have not been rigorously evaluated in younger populations. This prospective cross-sectional study determined the specificity of multitarget stool DNA (mt-sDNA) test an average-risk population 45 49 year-olds. Specificity was primary outcome and measured participants without or advanced precancerous lesions [APL– adenomas (AA),...
<div>Abstract<p>High-specificity colorectal cancer screening is desirable to triage patients <50 years for colonoscopy; however, most endorsed tests have not been rigorously evaluated in younger populations. This prospective cross-sectional study determined the specificity of multitarget stool DNA (mt-sDNA) test an average-risk population 45 49 year-olds. Specificity was primary outcome and measured participants without or advanced precancerous lesions [APL– adenomas (AA),...
INTRODUCTION: Colorectal cancer (CRC) incidence and mortality rates in the ≥55 year old population is decreasing, while CRC increasing those < 55 years (SEER Cancer Stat Facts: Cancer. NCI, Bethseda, MD). Recently, American Society revised its screening guidelines to recommend initiation at age 45 for average-risk individuals (American Society, 2018). To date, most endorsed tests have not been rigorously studied younger groups. In this study, we examined point sensitivity of multi-target...
INTRODUCTION: Due to the rising incidence and mortality of colorectal cancer (CRC) in individuals < 55 years (Siegel R, et al, JNCI, 2017), American Cancer Society (ACS) guidelines now recommend average-risk CRC screening beginning at age 45 years. The multi-target stool DNA (mt-sDNA) test, an FDA-approved test for ≥50 years, is one ACS-recommended option this group. To minimize invasive testing younger group, a with high specificity necessary triage patients diagnostic colonoscopy. date,...
Abstract Background Most colorectal cancer (CRC) screening tests have not been rigorously studied in younger age groups. Aims To estimate sensitivity of the multi-target stool DNA (mt-sDNA) test patients ages 45-49 years. Methods We identified archived samples (Exact Sciences; Madison, WI) from individuals years who had completed an index colonoscopy and confirmed diagnoses CRC or advanced precancerous lesions (APL; defined as high-grade dysplasia, >25% villous morphology, ≥1 cm size...